Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

Eradication of spontaneous malignancy by local immunotherapy

(2018) Idit Sagiv-Barfi et al.   Science Translational Medicine

Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model

(2017) Shekhar K. Gadkaree et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways

(2017) Kai Li et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Thermosensitive Gel–Based Formulation for Intratumoral Delivery of Toll-Like Receptor 7/8 Dual Agonist, MEDI9197

(2017) Amir Fakhari et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Anti-tumor Activity of Toll-Like Receptor 7 Agonists

(2017) Huju Chi et al.   Frontiers in Pharmacology

A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines

(2017) Neal Van Hoeven et al.   Scientific Reports

Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach

(2016) Christopher B. Fox et al.   JOURNAL OF CONTROLLED RELEASE

Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+T cells

(2016) Shu Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy

(2016) Simon J. Dovedi et al.   Oncotarget

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

(2016) Suzanne I.S. Mosely et al.   Cancer Immunology Research

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy

(2016) Hasan Rehman et al.   Journal for ImmunoTherapy of Cancer

Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma

(2015) A. H. Rook et al.   BLOOD

Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy

(2015) Kevin J Harrington et al.   Expert Review of Anticancer Therapy

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Clinical Trial Evidence of the Antitumor Activity of Topical Imiquimod for Breast Cancer Skin Metastases

(2014) Sylvia Adams et al.   JOURNAL OF CLINICAL ONCOLOGY

Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation

(2014) Manisha Singh et al.   JOURNAL OF IMMUNOLOGY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Therapeutic In Situ Autovaccination against Solid Cancers with Intratumoral Poly-ICLC: Case Report, Hypothesis, and Clinical Trial

(2014) A. M. Salazar et al.   Cancer Immunology Research

Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors

(2014) By Zhao et al.   Journal for ImmunoTherapy of Cancer

TLR7 Stimulation of APCs Results in Inhibition of IL-5 through Type I IFN and Notch Signaling Pathways in Human Peripheral Blood Mononuclear Cells

(2013) S. Edwards et al.   JOURNAL OF IMMUNOLOGY

Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8+T-cell responses in melanoma patients

(2012) Simone M. Goldinger et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

TLR-7 and -8 agonists as vaccine adjuvants

(2011) Mark A Tomai et al.   Expert Review of Vaccines

Vaccine adjuvant activity of 3M-052: An imidazoquinoline designed for local activity without systemic cytokine induction

(2011) Dmitri Smirnov et al.   VACCINE

Potentiation of the antitumor effects of imidazoquinoline immune response modifiers by cyclophosphamide

(2010) Calin D. Dumitru et al.   CANCER BIOLOGY & THERAPY

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

(2010) Joshua D. Brody et al.   JOURNAL OF CLINICAL ONCOLOGY

The antiviral activity of toll-like receptor 7 and 7/8 agonists

(2009) R.L. Miller et al.   DRUG NEWS & PERSPECTIVES

A phase II dose-ranging study of topical resiquimod to treat actinic keratosis

(2008) R.-M. Szeimies et al.   BRITISH JOURNAL OF DERMATOLOGY

An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma

(2008) R. Dummer et al.   CLINICAL CANCER RESEARCH